Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Personalis Inc PSNL

Healthcare Diagnostics & Research
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole... see more

Current News (NDAQ:PSNL)

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

Business Wire 5 days ago

Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Business Wire February 26, 2026

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Business Wire February 17, 2026

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Business Wire February 12, 2026

Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance

Business Wire February 10, 2026

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

Business Wire February 2, 2026

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Business Wire January 28, 2026

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker(TM)

Business Wire January 12, 2026

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

Business Wire January 8, 2026
View More News ››

Opinion & Analysis (NDAQ:PSNL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PSNL)

This stock is a good buy and

A good hold for a long position.It is a promising one in the biotech and pharmaceutical field.
coolfooldumbguy - December 20, 2024

Personalis, Inc. (NASDAQ:PSNL): Establishing a Leading Posit

http://beyondspx.com/2024/08/01/personalis-inc-nasdaqpsnl-establishing-a-leading-position-in-the-rapidly-growing-mrd-testing-market/
MikeTester - August 2, 2024
View more Bullboard ››

Silvercorp Metals Inc

Silvercorp Metals Inc

Silvercorp Metals Inc., together with its subsidiaries, acquires, explores, develops, and mines mineral properties in China ...
View More »

Podcasts